coronary heart disease patients who underwent primary PCI with stenting
Conditions
Interventions
Group A:Stop clopidogrel directly, only aspirin 100mg/d
Group B:Aspirin 200mg/d for three months, and then decease
Group C:the first month: clopidogrel 75mg/qod
the second month: clopidogrel 75mg, every three days
the third month: clopidogrel 75mg, every four days
the fourth month: stop clopidogrel, during clopidogrel decrement, aspirin 100mg/d will be taken
Group D:to continue clopidogrel 75mg/d+ aspirin 100mg/d for 3 months, and then stop clopidogrel, only aspirin 100mg/d
Sponsors
The Fourth Affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: patients who underwent primary PCI with stenting
Exclusion criteria
Exclusion criteria: patients who regularly had clopidogrel, hypersusceptible to aspirin and clopidogrel, with a history of alimentary tract hemorrhage, bleeding diathesis, platelet dysfunction, had an adverse event while receiving clopidogrel therapy, PT>1.5 controlled, platelet count <10*10^9/L, hemoglobin <90 g/L.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cardiovascular events;Mortality, AMI; | — |
Secondary
| Measure | Time frame |
|---|---|
| platelet aggregation, CRP, P-selectin, haemorrhage; | — |
Countries
China
Contacts
Public ContactYang Fan
Outcome results
None listed